Abstract
Neurodegenerative disorders are devastating human diseases that include Parkinsons, Huntingtons, Alzheimers, amyotrophic lateral sclerosis, and the frontal temporal dementias. Although the clinical manifestations of these disorders have been known for quite some time, our understanding of the molecular underpinnings is only starting to emerge. Protein misfolding and aggregation is a common hallmark among these diseases, and produce a number of cellular and functional alterations. The loss of dopaminergic neurons in the substantia nigra justified the use of dopaminergic therapies in patients. However, these strategies do not appear to confer disease-modifying effects, and do not prevent progression. The idea that neurotrophic factors might promote cell survival is an attractive one. Existing evidence from clinical trials is currently inconclusive, but some patients display clear clinical benefits. Thus, the current challenge is to develop novel strategies that make the use of neurotrophic factors more consistent.
Keywords: Parkinson's disease, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, glial cell line derived neurotrophic factor, se, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, frontal temporal dementias, parkinsonism, BDNF, GDNF, NGF, (MAPK) pathway, neurturin, neublastin, enovin, persephin, (PSPN), TrK-mediated neurotrophin signaling, hyponatremia, Unified Parkinson's Disease Rating Scale, UPDRS, dyskinesias, L-Dopa-induced dyskinesias
CNS & Neurological Disorders - Drug Targets
Title: Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
Volume: 9 Issue: 6
Author(s): Maria Jose Diogenes and Tiago Fleming Outeiro
Affiliation:
Keywords: Parkinson's disease, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, glial cell line derived neurotrophic factor, se, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, frontal temporal dementias, parkinsonism, BDNF, GDNF, NGF, (MAPK) pathway, neurturin, neublastin, enovin, persephin, (PSPN), TrK-mediated neurotrophin signaling, hyponatremia, Unified Parkinson's Disease Rating Scale, UPDRS, dyskinesias, L-Dopa-induced dyskinesias
Abstract: Neurodegenerative disorders are devastating human diseases that include Parkinsons, Huntingtons, Alzheimers, amyotrophic lateral sclerosis, and the frontal temporal dementias. Although the clinical manifestations of these disorders have been known for quite some time, our understanding of the molecular underpinnings is only starting to emerge. Protein misfolding and aggregation is a common hallmark among these diseases, and produce a number of cellular and functional alterations. The loss of dopaminergic neurons in the substantia nigra justified the use of dopaminergic therapies in patients. However, these strategies do not appear to confer disease-modifying effects, and do not prevent progression. The idea that neurotrophic factors might promote cell survival is an attractive one. Existing evidence from clinical trials is currently inconclusive, but some patients display clear clinical benefits. Thus, the current challenge is to develop novel strategies that make the use of neurotrophic factors more consistent.
Export Options
About this article
Cite this article as:
Jose Diogenes Maria and Fleming Outeiro Tiago, Neurotrophic Factors as a Protective Strategy in Parkinsons Disease, CNS & Neurological Disorders - Drug Targets 2010; 9 (6) . https://dx.doi.org/10.2174/187152710793237449
DOI https://dx.doi.org/10.2174/187152710793237449 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tau Protein Aggregation in Alzheimer's Disease: Recent Advances in the Development of Novel Therapeutic Agents
Current Pharmaceutical Design An Image-based Mouth Switch for People with Severe Disabilities
Recent Patents on Computer Science Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review
Current Drug Targets Effects of Therapeutic Hypothermia on the Glial Proteome and Phenotype
Current Protein & Peptide Science The Role of Oxidative Stress in Depressive Disorders
Current Pharmaceutical Design Dietary Polyphenols for Treatment of Alzheimer’s Disease– Future Research and Development
Current Pharmaceutical Biotechnology Somatostatin and Cognitive Function in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry A Novel Approach for Substitution of Sulfonate Group by (1H)-imidazole moiety: An Application for Synthesis of Novel Benzyl Imidazolyl carbamates
Letters in Organic Chemistry Stem Cell Based Preclinical Drug Development and Toxicity Prediction
Current Pharmaceutical Design Dysregulation of RNA Mediated Gene Expression in Motor Neuron Diseases
CNS & Neurological Disorders - Drug Targets SOD1 Aggregation and ALS: Role of Metallation States and Disulfide Status
Current Topics in Medicinal Chemistry Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning
Current Neuropharmacology Alzheimer's Disease and Natural Products: Future Regimens Emerging from Nature
Current Topics in Medicinal Chemistry Screening of Early and Late Onset Alzheimer’s Disease Genetic Risk Factors in a Cohort of Dementia Patients from Liguria, Italy
Current Alzheimer Research Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design Cholesterol, Alzheimers Disease, Prion Disorders: A menage a trois?
Current Drug Targets Chemical and Pharmacological Aspects of Heteroaryl-Nitrones
Current Medicinal Chemistry Cation-Responsive MRI Contrast Agents Based on Gadolinium(III)
Current Inorganic Chemistry (Discontinued) Molecular Biomarkers for Amyotrophic Lateral Sclerosis
Current Bioinformatics Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets